Acadia Pharmaceuticals (ACAD) Share-based Compensation (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Share-based Compensation of $14.7 million for Q1 2026, up 29.16% year-over-year from $11.4 million in Q1 2025, and up 11.05% quarter-over-quarter from $13.2 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Share-based Compensation (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $14.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 29.16% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $55.5 million (down 12.92% YoY), while the FY2025 annual figure was $52.1 million, down 22.24% from the prior year.
- Share-based Compensation for Q1 2026 stood at $14.7 million, up from $13.2 million in the prior quarter.
- The five-year high for Share-based Compensation was $26.2 million in Q3 2024, with the low at -$43.2 million in Q4 2023.
- The 5-year median for Share-based Compensation is $14.7 million (2023), against an average of $12.2 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 399.69% in 2023, then soared 124.19% in 2024.
- Acadia Pharmaceuticals' Share-based Compensation stood at $14.4 million in 2022, then slumped by 399.69% to -$43.2 million in 2023, then jumped by 124.19% to $10.4 million in 2024, then advanced by 26.65% to $13.2 million in 2025, then advanced by 11.05% to $14.7 million in 2026.
- Business Quant data shows ACAD's Share-based Compensation at $14.7 million in Q1 2026, $13.2 million in Q4 2025, and $13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 16.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.94 Mn |
| Jun 30, 2026 | 16.94 Mn |
| Mar 31, 2026 | 14.70 Mn |
| Mar 31, 2026 | 14.70 Mn |
| Dec 31, 2025 | 13.24 Mn |
| Dec 31, 2025 | 13.24 Mn |
| Sep 30, 2025 | 13.18 Mn |
| Sep 30, 2025 | 13.18 Mn |
| Jun 30, 2025 | 14.34 Mn |
| Jun 30, 2025 | 14.34 Mn |
| Mar 31, 2025 | 11.38 Mn |
| Mar 31, 2025 | 11.38 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 26.16 Mn |
| Sep 30, 2024 | 26.16 Mn |
| Jun 30, 2024 | 15.69 Mn |
| Jun 30, 2024 | 15.69 Mn |
| Mar 31, 2024 | 14.75 Mn |
| Mar 31, 2024 | 14.75 Mn |